Pulmatrix, Inc.

Overview

Symbol: PULM
Exchange: NASDAQ
Current Price: $1.26
Change: +$0.02 (1.61%)

Recent Price Information

• At close: Apr 30, 4:00:00 PM EDT
• After-hours: Apr 30, 4:00:26 PM EDT

Stories & Analysis

• No China sales cut Pulmonx revenue 9%, but 2026 forecast holds
  Stock Titan · Apr 28, 2026

• Eos-backed investor takes 9.99% Pulmatrix (PULM) stake ahead merger
  Stock Titan · Apr 21, 2026

• Pulmatrix announces closing of preferred stock transaction as part of planned merger
  marketscreener.com · Apr 20, 2026

• A $1M cash infusion gives Pulmatrix working capital as Eos merger advances
  Stock Titan · Apr 20, 2026

Key Issues

Merger with Eos SENOLYTIX: Strategic opportunity or risky pivot?

Bullish view

The planned merger with Eos SENOLYTIX, backed by the closing of the Series B Convertible Preferred Stock transaction, signals a concrete strategic step forward. The CEO described it as 'an important initial step forward,' suggesting management confidence in the deal's potential to unlock new value for shareholders.

Bearish view

The merger raises serious execution risks. The $1M raised is a modest capital infusion, and the $2.20 conversion price is significantly above the current stock price of $1.34, pointing to deep dilution concerns. The company's ability to complete the transaction and maintain Nasdaq compliance remains highly uncertain.

Company Information

• Symbol: PULM
• IPO Date: Mar 20, 2014
• CEO: Peter Ludlum
• Fulltime Employees: 2
• Sector: Healthcare
• Industry: Biotechnology
• Country: United States

Earnings History

EPS Revenue